Who owns Celldex Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of CLDX from SEC Form 13F filings across 250 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 250 institutions disclosed 89.6M shares of Celldex Therapeutics, Inc. worth $2.90B — about 114% of shares outstanding; the largest disclosed holder is WELLINGTON MANAGEMENT GROUP LLP. Source: SEC Form 13F filings, parsed by EvidInvest.
250
13F holders
$2.90B
value, 2026 filers
114%
of shares outstanding (89.6M sh)
40
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of CLDX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | WELLINGTON MANAGEMENT GROUP LLP | 10.7M | $345.9M | 0.1% | 13.6% | +11.8% |
| 2 | FMR LLC | 8.6M | $279.9M | 0.0% | 11% | +132.0% |
| 3 | BlackRock, Inc. | 6.9M | $225.2M | 0.0% | 8.8% | -0.8% |
| 4 | Kynam Capital Management, LP | 5.1M | $164.2M | 9.1% | 6.5% | -4.8% |
| 5 | PRICE T ROWE ASSOCIATES INC /MD/ | 4.4M | $142.1M | 0.0% | 5.6% | -6.4% |
| 6 | STATE STREET CORP | 3.5M | $112.7M | 0.0% | 4.4% | -10.8% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 3.5M | $112.7M | 0.0% | 4.4% | +0.3% |
| 8 | BAKER BROS. ADVISORS LP | 2.6M | $83.1M | 0.4% | 3.3% | +116.9% |
| 9 | Deep Track Capital, LP | 2.1M | $68.9M | 1.1% | 2.7% | -27.7% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.0M | $66.4M | 0.0% | 2.6% | +1.3% |
| 11 | EVENTIDE ASSET MANAGEMENT, LLC | 1.9M | $61.5M | 0.9% | 2.4% | +82.9% |
| 12 | GOLDMAN SACHS GROUP INC | 1.6M | $52.5M | 0.0% | 2.1% | +0.2% |
| 13 | Driehaus Capital Management LLC | 1.4M | $45.3M | 0.3% | 1.8% | +41.3% |
| 14 | Fisher Asset Management, LLC | 1.2M | $40.4M | 0.0% | 1.6% | +26.5% |
| 15 | Eversept Partners, LP | 1.2M | $38.1M | 2.0% | 1.5% | -34.2% |
| 16 | Affinity Asset Advisors, LLC | 1.2M | $37.6M | 1.5% | 1.5% | +65.8% |
| 17 | DIMENSIONAL FUND ADVISORS LP | 1.1M | $37.2M | 0.0% | 1.5% | +6.9% |
| 18 | Elmind Capital, LP | 1.1M | $36.0M | 8.9% | 1.4% | +12.1% |
| 19 | FEDERATED HERMES, INC. | 1.0M | $34.0M | 0.0% | 1.3% | +113.0% |
| 20 | AMERICAN CENTURY COMPANIES INC | 1.0M | $33.9M | 0.0% | 1.3% | +0.3% |
| 21 | Commodore Capital LP | 1.0M | $32.4M | 2.5% | 1.3% | -25.9% |
| 22 | NOVO HOLDINGS A/S | 950,000 | $30.8M | 2.1% | 1.2% | -7.3% |
| 23 | UBS Group AG | 929,277 | $30.1M | 0.0% | 1.2% | +92.8% |
| 24 | VANGUARD PORTFOLIO MANAGEMENT LLC | 906,135 | $29.4M | 0.0% | 1.2% | +4.9% |
| 25 | Frazier Life Sciences Management, L.P.NEW | 900,080 | $29.2M | 0.7% | 1.1% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.